iBio (IBIO) Projected to Post Quarterly Earnings on Friday

iBio (NYSEAMERICAN:IBIO) will likely be issuing its Q4 2025 results before the market opens on Friday, September 19th. Analysts expect the company to announce earnings of ($0.2950) per share and revenue of $0.10 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earningoverview page for the latest details on the call scheduled for Friday, September 5, 2025 at 9:00 AM ET.

iBio Price Performance

Shares of IBIO opened at $0.96 on Friday. The stock has a fifty day moving average price of $0.75 and a 200 day moving average price of $1.62. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91. iBio has a 12 month low of $0.56 and a 12 month high of $6.89.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.